Valproic acid sensitizes trail-resistant anaplastic thyroid carcinoma cells to apoptotic cell death

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Cha, Hyun Young ^a   Lee, Bok Soon ^a   Kang, Sam ^a   Shin, Yoo Seob ^a   Chang, Jae Won ^a   Sung, Eun Sil ^a   Kim, Yong Sung ^a   Choi, Jae Won ^a   Kim, Jang Hee ^a   Kim, Chul Ho ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; PROTEIN BID; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; X LINKED INHIBITOR OF APOPTOSIS; ANTICONVULSIVE AGENT; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID CARCINOMA; WESTERN BLOTTING; CELL PROLIFERATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; THYROID NEOPLASMS; TUMOR CELL CULTURE;

ANTICONVULSANTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOENZYME TECHNIQUES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VALPROIC ACID;

EID: 84892789289     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3232-y     Document Type: Article

References (41)

1. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol. 2002;3(7):407-14.
2. Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995;17(1):41-7; discussion 47-8.
3. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol. 2003;15(1):78-83.
4. Conticello C, Adamo L, Giuffrida R, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab. 2007;92(5):1938-42.
5. Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancerderived cell lines. Endocr Relat Cancer. 2008;15(2):559-68.
6. Libertini S, Abagnale A, Passaro C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer. 2011;18(1):129-41.
7. Wunderlich A, Roth S, Ramaswamy A, et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine. 2012;42(3):637-46.
8. Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene. 2000; 19(30):3363-71.
9. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66-75.
10. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003;13(2):135-47.
11. Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res. 2012;318(13): 1564-76.
12. Kahana S, Finniss S, Cazacu S, et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal. 2011;23(8):1348-57.
13. Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis. 2010;15(10):1256-69.
14. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010;9(12):3254-66.
15. Iacomino G, Medici MC, Russo GL. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res. 2008;28(2A):855-64.
16. Brautigam K, Biernath-Wupping J, Bauerschlag DO, et al. Combined treatment with TRAIL and PPARc ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol. 2011;137(5):875-86.
17. Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2002;50(1):46-52.
18. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAILR2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 2004;23(37):6261-71.
19. Nightingale KP, O'Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Gen Dev. 2006;16(2):125-36.
20. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Gen Dev. 1999;9(1):40-8.
21. Csordas A. On the biological role of histone acetylation. Biochem J. 1990;265(1):23-38.
22. Fulda S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp Cell Res. 2012;318(11):1208-12.
23. Perego P, Zuco V, Gatti L, Zunino F. Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol. 2012; 83(8):987-94.
24. Frew AJ, Lindemann RK, Martin BP, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA. 2008;105(32): 11317-22.
25. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269(1):7-17.
26. Lee BS, Cha HY, Shin YS, Kim YS, Kim CH. AY4, an agonistic anti-death receptor 4 monoclonal antibody, induces apoptotic cell death in anaplastic thyroid cancer cells via down-regulation of Bcl-xL with reactive oxygen species generation. Endocr Relat Cancer. 2013;20:283-91.
27. Lee BS, Kang SU, Hwang HS, et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett. 2012;322(1):45-57.
28. Lim YC, Park HY, Hwang HS, et al. (-)-Epigallocatechin-3- gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 2008;271(1): 140-52.
29. Kim CH, Koh YW, Han JH, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010;32(12):1655-64.
30. Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A. The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 2002;22(24):8571-9.
31. Muscarella DE, Bloom SE. The contribution of c-Jun N-terminal kinase activation and subsequent Bcl-2 phosphorylation to apoptosis induction in human B-cells is dependent on the mode of action of specific stresses. Toxicol Appl Pharmacol. 2008;228(1): 93-104.
32. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40.
33. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12(18):5570-7.
34. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Investig New Drugs. 2005;23(2):99-109.
35. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res. 2004;298(2):560-73.
36. Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res. 2001; 61(11):4450-8.
37. Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, Sen E. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med. 2010;14(8):2151-61.
38. Xiao D, Pinto JT, Soh JW, et al. Induction of apoptosis by the garlicderived compound S-allylmercaptocysteine (SAMC) is associated with microtubule depolymerization and c-Jun NH(2)-terminal kinase 1 activation. Cancer Res. 2003;63(20):6825-37.
39. Benoit M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells. J Surg Res. 2011;167(2):e193-8.
40. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. Biol Chem. 2004;279(1):51-60.
41. Hwang MK, Ryu BJ, Kim SH. AW00179 potentiates TRAILmediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and downregulation of anti-apoptotic molecules. Amino Acids. 2012; 43(4):1679-87.